Vitamin B2 80% Pharma Grade API for Tablet / Capsule / Granule / Injection, Oral & Injectable is a riboflavin-based pharmaceutical intermediate with a nominal 80.0% w/w riboflavin content on the dried basis. The active moiety is riboflavin, CAS 83-88-5, molecular formula C₁₇H₂₀N₄O₆ and molecular weight 376.36 g/mol. The model designation “Vitamin B2 80% Pharma Grade API” is a grade identifier rather than a Ph. Eur. or USP monograph title; neat riboflavin API is typically released at 98.0%–102.0% on the dried basis under the USP monograph, while the 80.0% product is a processed composition in which the balance is defined by the manufacturer’s approved carrier system. For formula replacement, each 100.0 mg of the product supplies 80.0 mg of riboflavin, corresponding to a replacement factor of 1.25 when neat riboflavin is substituted in a bill of materials. This conversion must be applied at the preblend stage, because subsequent lubrication and compression steps do not change the arithmetic ratio.

Release controls for non-sterile oral API use include HPLC assay with UV detection near 444 nm, organic impurity resolution for lumiflavin and lumichrome, residual solvents under ICH Q3C, elemental impurities under ICH Q3D using Ph. Eur. 2.4.20 or USP <232>/<233>, and microbial limits by Ph. Eur. 2.6.12/2.6.13 or USP <61>/<62>. System suitability for HPLC should include resolution between lumiflavin and riboflavin of not less than 1.5, tailing factor not more than 2.0, and injection precision RSD not more than 2.0%, consistent with the applicable chromatographic chapter. Because the product is not a neat monograph substance, the certificate of analysis and approved dossier remain the controlling specification; published data for this specific configuration is limited in the public domain.

Separation from feed-grade riboflavin 80% is not only a label distinction. Feed-grade materials may be manufactured under feed additive quality systems and may carry silica, vegetable oil, or cereal carriers that do not appear in human pharmacopoeial formularies. Their elemental impurity profile is not controlled under ICH Q3D, and their solvent residues may not meet ICH Q3C. The pharma grade 80% product must be manufactured under ICH Q7, with change-control oversight for the carrier and full batch traceability. If a buyer attempts to qualify feed-grade material as a pharmaceutical input, the difference commonly appears in the residual solvent profile, the microbiological screening, and the particle-size reproducibility rather than only in the riboflavin assay.

What Limits Direct Compression of the 80% Grade in Low-Dose Tablets?

Direct compression is constrained by riboflavin’s native needle-like crystal habit, by blend segregation, and by static charging. The 80% spray-dried or granulated grade is designed to reduce flow problems, but its carrier can dominate the lower end of the particle-size distribution and create assay stratification if the blend is over-agitated. For a 10 mg riboflavin tablet, the required 12.5 mg of grade represents 6.25% w/w of a 200 mg total tablet weight. At that level, USP <905> uniformity of dosage units can produce acceptance values above 15.0 unless a staged preblend is used. A typical preblend sequence consists of a first pass at 1:5 active-to-diluent ratio with microcrystalline cellulose or spray-dried lactose, followed by addition of disintegrant and final blending with a low-shear V-blender or bin blender. Paddle speed and feed shoe rotation on a rotary press should be set to avoid powder fluidisation because low-humidity air below 30% RH increases electrostatic adhesion of the fine riboflavin fraction to stainless steel contact surfaces.

Tabletability of the 80% grade is not identical to that of neat riboflavin because the carrier modifies yield pressure and elastic recovery. Excipient selection should avoid over-lubrication with magnesium stearate above 1.0% w/w; excessive shear from high-speed blending can delaminate the carrier coating and release poorly compactible riboflavin needles, producing capping or split crowns on compaction. If direct compression is used, main compression force should be established on an instrumented press using compaction profiling, and tablet porosity should be kept within the range that supports disintegration below 30 min for uncoated tablets or the relevant compendial disintegration time. Precompression force may be required if elastic recovery exceeds 2.0% after ejection; the exact value is tooling-dependent.

Wet granulation of the 80% grade presents a different control problem. Aqueous binder addition can partially dissolve riboflavin at the granulation liquid front, and drying can cause migration of dissolved active to granule surfaces. If the carrier is a hygroscopic polysaccharide, high-shear wet massing above 10.0% LOD can produce tacky agglomerates and increase torque on the impeller. Fluid-bed drying should be used with a final granule moisture limit established from the approved finished product dossier; typical loss-on-drying values for oral granule intermediates fall below 5.0%, but the supplier’s limit may be tighter for this grade. Sieve analysis after milling should include a 850 µm coarse screen and a 150 µm fines screen to track oversize granules and excessive fines; both fractions affect flow and capsule fill. Riboflavin colour is not a reliable indicator of blend homogeneity because light exposure can lighten granules without a proportional loss of total riboflavin as measured by HPLC.

Hard capsule filling is governed by shell capacity and bulk density. For a size 3 capsule containing 10 mg riboflavin, the 12.5 mg of 80% grade is diluted with filler to a practical fill weight; if the grade has a low bulk density, dosator or auger fill systems may require tamping adjustments. Content uniformity testing is controlled under USP <905> when the active-to-fill ratio is below 25.0%. Empty capsules should be stored below 60% RH before filling, and filled capsules should be packed in opaque blisters or amber containers because riboflavin is light-sensitive in the solid state.

For sachet and dry syrup formats, the 80% grade is usually blended with sucrose or sorbitol and a flow agent. The bulk density and angle of repose of the final sachet powder determine dosing reproducibility on auger fillers. The target fill weight coefficient of variation should be below 2.0% for dose-critical products; the 80% grade’s carrier may decrease or increase static depending on ambient relative humidity. If flow is marginal, addition of colloidal silicon dioxide at 0.1–0.5% w/w and a suitable glidant can reduce angle of repose below 40°, but the exact level must be validated because excess glidant can depress blend density and increase segregation.

If an Injectable Solution Is Made from the 80% Grade, What Preformulation Limits Must Be Addressed?

The 80% grade is not automatically suitable for aqueous injection. Neat riboflavin has very slight water solubility, often cited as approximately 0.1 mg/mL at 25 °C, while riboflavin 5′-phosphate sodium is freely soluble and is the usual injectable form. A parenteral process using the 80% grade must therefore include a documented conversion to the phosphate salt or a pharmacopoeially acceptable solubilisation system such as nicotinamide and pH adjustment. Simple aqueous dilution without such a step risks incomplete dissolution and particulate failure. If the finished product is sterilised by 0.22 µm membrane filtration, prefiltration clarification is required because residual undissolved riboflavin fines can block the membrane and raise differential pressure above the filter specification. Terminal sterilisation at 121 °C for 15 min may be acceptable for the phosphate ester solution but must be validated for photodegradation products and pH drift. Light exposure during aseptic filling should be controlled with amber or red light; aqueous riboflavin solutions can form lumiflavin and lumichrome under white light.

For injectable use, depyrogenation is a release criterion in addition to sterility. A limit such as <0.5 EU/mg may be appropriate depending on the maximum daily dose and route, but the exact acceptance limit is calculated from the intended dose and the pharmacopoeial monograph. Substitution of the 80% grade for riboflavin 5′-phosphate sodium in a marketed parenteral formula without stability, bioequivalence and particulate bridging is not acceptable. The sodium content of the phosphate salt must also be considered in formulations with sodium-restricted labelling; the 80% plain riboflavin grade does not automatically avoid this issue because carrier composition and the salt form must be verified for each lot.

Packaging and storage of the 80% pharma grade should follow light-protective and moisture-control practice. Bulk packing in a double polyethylene liner inside a fibre drum with an outer light barrier is typical; clear polyethylene bags are not suitable for extended storage because riboflavin absorbs in the UV and visible regions. Storage below 25 °C in a dry environment is appropriate, and exposure to relative humidity above 60% should trigger re-qualification when the carrier is hygroscopic. If the product is received with a certificate of analysis that does not state the assay interval, loss-on-drying, residue on ignition, or the carrier monograph, the material should be quarantined and evaluated against the finished product risk assessment before use.

Cleaning validation in multi-product pharmaceutical facilities should account for riboflavin’s strong colour and fluorescence; visual inspection alone may not detect low residues on stainless steel under certain lighting. Swab sampling with HPLC detection near 444 nm is used, with acceptance limits derived from maximum allowable carryover and the next product’s batch size. Strong oxidising agents can degrade riboflavin and should be avoided in cleaning procedures unless equipment is fully rinsed before subsequent manufacturing. The operational boundary for this product is therefore set by light control, moisture management, and the strict separation of oral and injectable process trains.